Syringe & Injection Needle Manufacturing in European Union: Market Size, Businesses & Forecast 2026

The syringe and injection needle manufacturing industry in the European Union comprises the production of essential medical drug delivery consumables, including hypodermic needles, prefilled syringes, and specialized infusion components. The sector's direction is heavily influenced by the transition to safer, sharper, and more advanced drug delivery methods, as well as strict regulatory compliance across member states. Demonstrating the scale of the broader context, European medical technology patent applications reached 15,700 applications in 2024 (source: MedTech Europe 2025 Report), highlighting a robust environment for innovation in medical devices.

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Syringe & Injection Needle Manufacturing in European Union industry cover?

This industry encompasses the fabrication of medical, surgical, and veterinary instruments intended for parenterally administering substances or extracting fluids. Under pan-European statistical standards, these items fall within the broader scope of physical medical device production rather than pharmaceuticals or electronic apparatus. Product lines include standard hypodermic syringes, safety-engineered needles, dental needles, insulin pens, and specialized cannulas.

• •Covers both plastic single-use and specialized glass syringe structures.
• •Includes advanced safety syringes featuring automatic needle retraction mechanisms.
• •Categorized under general non-chemical medical consumables intended for hospital and home care use.

Who operates in the industry and how is it structured?

The European operating landscape features a mixture of large multinational manufacturing plants and highly specialized regional small-to-medium enterprises. Production is strategically concentrated in member states with high industrial output and strong engineering infrastructure, notably Germany, France, and Ireland. The broader medical technology ecosystem in Europe supports over 930,000 jobs across 38,000 companies, according to industry data from 2025.

• •Small and medium-sized enterprises (SMEs) account for approximately 90% of the broader European medical technology corporate count as of 2025.
• •Germany represents the highest absolute employment hub within the European medical technology space, providing 212,100 direct jobs in 2025.
• •Ireland and Switzerland exhibit the highest concentration of medical technology employees per capita in Europe.

What drives demand in the industry?

Demand is fundamentally underpinned by shifting demographic patterns, specifically the rapidly aging population of the European Union, which increases the prevalence of chronic illnesses. Conditions requiring continuous or daily subcutaneous injections, such as diabetes and autoimmune diseases, provide a stable baseline for consumable volume requirements. Furthermore, public health policies emphasizing healthcare worker safety from needlestick injuries mandate the procurement of high-value safety-engineered devices.

• •An estimated 60 million people across Europe live with diabetes, acting as a major driver for insulin syringe and pen-needle production.
• •EU-wide healthcare expenditure allocates roughly 7.6% of its total budget to medical technologies.
• •Per capita spending on overall medical technology within Europe averaged approximately 265 Euros according to historical benchmark figures.

Who are the notable companies in the industry?

The European marketplace is contested by prominent global healthcare conglomerates with extensive local manufacturing footprints alongside domestic European public and private operators. Companies compete primarily on manufacturing precision, supply chain reliability, regulatory approval velocity, and proprietary safety features. Large-scale automation is heavily utilized by these market participants to maintain competitive unit economics across European factories.

• •Becton, Dickinson and Company (BD) operates massive medical delivery and syringe manufacturing facilities within the EU, including major sites in Ireland and France.
• •B. Braun Melsungen AG is a prominent European-based medical manufacturer distributing extensive lines of Omnican and Injekt syringes.
• •Gerresheimer AG is an EU-headquartered public manufacturer specializing in high-quality glass and plastic prefillable syringe systems.
• •Terumo Corporation maintains robust European commercial and production operations, distributing advanced hypodermic needles and dental injection systems.

What are the recent trends and outlook?

A prominent trend in the manufacturing process is the transition from standard disposable options to sophisticated prefilled syringe systems integrated directly by pharmaceutical companies. Innovation is tightly linked to intellectual property generation, with medical technology consistently tracking as one of Europe's top sectors for new filings. Environmental sustainability mandates are also forcing producers to explore bio-based plastics and reduced packaging designs.

• •Medical technology registered 15,700 patent applications with the European Patent Office (EPO) in 2024.
• •The sector ranks as the 4th highest industry for total patent applications filed in Europe.
• •The ratio of granted patents to patent applications in European medical technology stood at 70.1% in 2024, reflecting high technical viability.

How is the industry regulated?

The commercialization and manufacture of syringes and needles within the European Union are governed by rigid legal frame conditions that dictate technical safety parameters. All products must successfully complete conformity assessments to carry the mandatory CE mark before entering the single market. The current framework emphasizes intensive post-market surveillance, precise risk classification, and stringent clinical evidence compilation.

• •Governed comprehensively by Regulation (EU) 2017/745, commonly known as the Medical Devices Regulation (MDR).
• •Syringes and injection needles are classified utilizing a risk-based tier system (Class I, IIa, IIb, or III) depending on invasive intent and pump-infusion status.
• •Producers must implement a certified Quality Management System complying strictly with the EN ISO 13485 standard.

Government, statistical and trade sources used for this Claight analysis.

• MedTech Europe Facts & Figures 2025 Report ·
• European Patent Office (EPO) Annual Statistics 2024 ·
• Eurostat NACE Rev. 2 Classification Database ·
• European Commission Medical Device Regulations (Regulation (EU) 2017/745)